Key facts
- This page summarizes David Scadden's Form 4 filing for Editas Medicine, Inc. (EDIT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2023, 16:30.
David Scadden - 01 Jun 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)
- Form type
- 4
- Accepted by SEC
- 05 Jun 2023, 16:30:24 UTC
- Previous filing
- 30 Jun 2022
- Next filing
- 15 Jun 2023
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ David Scadden
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
David Scadden filed Form 4 for Editas Medicine, Inc. (EDIT) on 05 Jun 2023.
Change
- Previous filing in this sequence was filed on 30 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EDIT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- Price
- $0.000000
- Shares after
- 25,000
- Date
- 01 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $9.55
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024.